Fluicell AB (OSTO:FLUI) Debt-to-Asset : 0.08 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLUI Fluicell AB OSTO:FLUI
47 GF Score
Price kr31.40
GF Value kr77.34
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Debt-to-Asset?

Fluicell AB OSTO:FLUI -0.32% 47 Debt-to-Asset is 0.08 as of Jun. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 47/100 and a GF Value™ of kr77.34 (Possible Value Trap). The stock has 4 warning signs investors should review.

Fluicell AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr2.00 Mil. Fluicell AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.00 Mil. Fluicell AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was kr25.01 Mil. Fluicell AB's debt to asset for the quarter that ended in Jun. 2026 was 0.08.

Fluicell AB  (OSTO:FLUI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Fluicell AB Debt-to-Asset Related Terms

Fluicell AB Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Debt-to-Asset Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fluicell AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.08

OSTO:FLUI vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Fluicell AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fluicell AB Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fluicell AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Fluicell AB's Debt-to-Asset falls into.


OSTO:FLUI
47GF Score
Fluicell AB OSTO:FLUI
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Fluicell AB's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 18.475
=0.00

Fluicell AB's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2 + 0) / 25.01
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.08 mean?
Fluicell AB (OSTO:FLUI) has a Debt-to-Asset of 0.08 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Fluicell AB and its competitors.
Is Fluicell AB's Debt-to-Asset too high?
Fluicell AB's current Debt-to-Asset is 0.08. Overall, Fluicell AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Debt-to-Asset compare to VRTX and REGN?
Fluicell AB's Debt-to-Asset of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Fluicell AB and its competitors. Fluicell AB's current Debt-to-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Possible Value Trap. The stock's GF Value™ is kr77.34, compared to a current price of kr31.40 — trading 59.4% below its estimated fair value. The current Debt-to-Asset is 0.08. Fluicell AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Debt-to-Asset is 0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of kr31.40 is trading 59.4% below its estimated GF Value™ of kr77.34. GuruFocus considers Fluicell AB to be Possible Value Trap.

Key valuation signals for OSTO:FLUI:

  • Debt-to-Asset: 0.08
  • GF Value™: kr77.34 vs. price of kr31.40 (59.4% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
47GF Score

Get the complete analysis for OSTO:FLUI

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr31.40
Price
kr77.34
GF Value